Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Discontinued Operations (2016 - 2018)

Soleno Therapeutics (SLNO) has disclosed Cash from Discontinued Operations for 3 consecutive years, with 188000.0 as the latest value for Q4 2018.

  • For Q4 2018, Cash from Discontinued Operations rose 66.61% year-over-year to 188000.0; the TTM value through Dec 2018 reached 1361000.0, up 55.1%, while the annual FY2018 figure was 1361000.0, 55.1% up from the prior year.
  • Cash from Discontinued Operations hit 188000.0 in Q4 2018 for Soleno Therapeutics, up from 405000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 188000.0 in Q4 2018 and bottomed at 2783000.0 in Q3 2016.
  • Average Cash from Discontinued Operations over 3 years is 855927.2, with a median of 648000.0 recorded in 2017.
  • Year-over-year, Cash from Discontinued Operations skyrocketed 73.66% in 2017 and then surged 41.61% in 2018.
  • Soleno Therapeutics' Cash from Discontinued Operations stood at 1384272.0 in 2016, then soared by 59.33% to 563000.0 in 2017, then surged by 66.61% to 188000.0 in 2018.
  • According to Business Quant data, Cash from Discontinued Operations over the past three periods came in at 188000.0, 405000.0, and 281000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.